Variations in statin prescribing for primary cardiovascular disease prevention: cross-sectional analysis by Fleetcroft, Robert et al.
Fleetcroft et al. BMC Health Services Research 2014, 14:414
http://www.biomedcentral.com/1472-6963/14/414RESEARCH ARTICLE Open AccessVariations in statin prescribing for primary
cardiovascular disease prevention: cross-sectional
analysis
Robert Fleetcroft1*†, Peter Schofield2† and Mark Ashworth2†Abstract
Background: Statins are an important intervention for primary and secondary cardiovascular disease (CVD) prevention.
We aimed to establish the variation in primary preventive treatment for CVD with statins in the English population.
Methods: Cross sectional analyses of 6155 English primary care practices with 40,017,963 patients in 2006/7. Linear
regression was used to model prescribing rates of statins for primary CVD prevention as a function of IMD (index of
multiple deprivation) quintile, proportion of population from an ethnic minority, and age over 65 years. Defined Daily
Doses (DDD) were used to calculate the numbers of patients receiving a statin. Statin prescriptions were allocated to
primary and secondary prevention based on the prevalence of CVD and stroke.
Results: We estimated that 10.5% (s.d.3.7%) of the registered population were dispensed a statin for any indication
and that 6.3% (s.d. 3.0%) received a statin for primary CVD prevention. The regression model explained 21.2% of
the variation in estimates of prescribing for primary prevention. Practices with higher prevalence of hypertension
(β co-efficient 0.299 p <0.001) and diabetes (β co-efficient 0.566 p < 0.001) prescribed more statins for primary prevention.
Practices with higher levels of ethnicity (β co-efficient-0.026 p <0.001), greater deprivation (β co-efficient −0.152 p <
0.001) older patients (β co-efficient −0.032 p 0.002), larger lists (β co-efficient −0.085, p < 0.001) and were more rural
(β co-efficient −0.121, p0.026) prescribed fewer statins. In a small proportion of practices (0.5%) estimated prescribing
rates for statins were so low that insufficient prescriptions were issued to meet the predicted secondary prevention
requirements of their registered population.
Conclusions: Absolute estimated prescribing rates for primary prevention of CVD were 6.3% of the population. There
was evidence of social inequalities in statin prescribing for primary prevention. These findings support the recent
introduction of a financial incentive for primary prevention of CVD in England.
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Cardiovascular disease (CVD) is the leading cause of
death in most developed countries, including the United
Kingdom (UK) [1]. Statins are effective in reducing mor-
tality and morbidity in patients with established coron-
ary heart disease and stroke (secondary prevention), and
also in people with higher levels of risk factors who have
not yet developed clinically manifest CVD (primary pre-
vention) [2]. The use of statins in both primary and* Correspondence: r.fleetcroft@uea.ac.uk
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unless otherwise stated.secondary prevention is supported by guidelines inter-
nationally [3-6]. Until recently, most guidelines recom-
mended treatment for primary prevention for those with a
20% or greater 10-year risk of developing CVD. The high
risk population for primary prevention includes most of
the elderly population, those with diabetes, and many with
hypertension. Recently the threshold of 10 year CVD risk
for primary prevention treatment has been lowered
to ≥7.5% in the USA, and ≥10% in England with all patients
over the age of 85 recommended the intervention [7,8].
In the England there are substantial financial incentives
for general practitioners (GPs) which encourage the use of
statins for secondary prevention of CVD, whereas untilral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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incentivised for patients diabetes [9]. In 2010, England in-
troduced a financial incentive for CVD risk calculation in
newly diagnosed hypertensive patients, and also NHS
Health Checks to people between the ages of 40 and
74 years [10]. Both measures are likely to have increased
awareness of the need for treatment with statins.
There is widespread evidence for variation in the
provision of treatment for secondary prevention of CVD,
including lower rates of statin prescribing in some ethnic
minority groups, the elderly, and those from lower socio-
economic classes [11-16]. However for the case of primary
prevention of CVD there is limited research into varia-
tions in prescribing rates of statins, possibly because there
is no routinely collected data for this prescribing indica-
tion. There are consistent findings from several small
studies that prescribing rates are lower than expected
when guideline recommendations are taken into account,
including the Netherlands, Norway, Canada, Australia and
England [17-22]. One study based in 12 European coun-
tries in 2006/7 reported that less than half of those eligible
for a statin for primary prevention received a prescription
[23]. One of the major goals of the Quality and Outcomes
Framework (QOF) is to reduce social inequalities in health
[24]. The QOF is a pay- for-performance contract intro-
duced in England and the UK in 2004, financially reward-
ing primary care practices for performance in clinical,
organisational, patient experience and additional services
[24]. Our aim was to conduct a study using modelling of
national routinely collected primary care data to estimate
the variation in the rate of statin prescribing for primary
CVD prevention. We also aimed to determine the role of
possible determinants of health inequalities such as age,
ethnicity and social deprivation.
Methods
Design
We performed a cross-sectional study with analysis at
the practice level. The study population included all gen-
eral practices in England with data available in 2006/7.
We used a definition of primary prevention which in-
cludes diabetes and hypertension, unless there is coexist-
ent heart disease or cerebrovascular disease [25].
Ethical approval
This study was granted ethical approval by the Faculty of
Medicine and Health sciences Research Ethics Committee,
Norwich Medical School, (reference 209/10-1066).
Prescribing data
We obtained prescribing data for statins from the ‘Prescrip-
tion and Pricings Division’ of the NHS Business Authority
for all practices in England in 2006/7. Prescribing volume
data are calculated from prescriptions issued in primarycare and dispensed by a pharmacist or dispensing surgery.
These data were standardised based on the ‘defined daily
doses’ (DDD) for each of the five statin drugs (atorvastatin,
fluvastatin, pravasatatin, rosuvastatin, simvastatin) plus one
combination drug (simvastatin with ezetimibe). The DDD
is an international measure of prescribing developed by the
World Health Organization and is the assumed average
maintenance dose per day for a drug used for its main indi-
cation in adults [26].
Practice and population characteristics data
We collected on practice and population characteristics
for all practices in England for the year 2006/7 except
where otherwise specified. We obtained data on the
practice characteristics known to influence prescribing
patterns from the General Medical Services database
[27]. We used data on ethnicity, deprivation status and
the percentage of the practice population over 65 years
of age as indicators sensitive to social inequalities. We
obtained ethnicity data from the 2001 census for the
geographical location (Lower Layer Super Output Area,
LLSOA) of each general practice. We combined the data
for South Asian, Black and Chinese groups to calculate a
practice level prevalence of ethnic minorities. We used
IMD quintiles of social deprivation based on LLSOAs in
2010 [28]. We obtained data on the prevalence of CVD,
stroke (including TIA), hypertension and diabetes from
the Information Centre for Health and Social Care [29].
Construction of framework to estimate prescribing rates
for primary prevention
As data on prescribing rates for statins for primary pre-
vention are not routinely collected for English primary
care we constructed a model in order to estimate the vol-
ume of statins prescribed for primary CVD prevention. A
worked example is displayed in Additional file 1. Firstly,
we calculated the number of patients receiving a statin for
any indication by adding together the statin DDDs and
dividing the total by 365 to estimate the number of pa-
tients receiving a statin over a year. Secondly, we multi-
plied this value by 1.25 to adjust for adherence, based on a
study of the size of the discrepancy between statin pre-
scribing for both primary and secondary prevention, and
dispensing of those prescriptions [30]. Thirdly, we esti-
mated the volume of statin prescribing in secondary pre-
vention based on the numbers of patients known to have
CVD or stroke, and assuming that all patients with estab-
lished CVD would be prescribed a statin. Fourthly, we
adjusted the estimated value for statin prescribing to ac-
count for comorbidity (as some patients will have had
both CVD and a stroke) using a method previously de-
scribed [31]. This method uses prevalence data from QOF
for each practice to estimate the proportion of the popula-
tion who have a comorbidity, in order to avoid double
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CVD and stroke. Finally, in order to estimate the volume
of statins prescribed for primary prevention, we deducted
the predicted numbers of patients eligible for secondary
prevention with statins from the total numbers of patients
receiving a statin. We expressed this number as a percent-
age of the practice population.
This model makes the following four assumptions. First
that all patients with CHD and stroke would be prescribed
a statin as recommended in current guidelines internation-
ally; second that the dose of statin used is the same as the
‘defined daily dose’; third that the adjustment for collection
of statin prescriptions is transferable from the US to the
English setting; and fourth that the co-morbidity correction
factor is an accurate estimate of true co-morbidity. We
tested these assumptions in sensitivity analyses.Statistical tests
We excluded practices from the analysis on the basis of
their list size (<1000 registered patients) as very small prac-
tices are likely to be atypical. We conducted descriptive
analyses and linear regression modelling using SPSS v18
(Chicago: SPSS Inc.). The outcome variable was the esti-
mated percentage of the practice population who were
treated with statins for primary prevention. The main ex-
planatory variables were 1) the percentage of the practice
population from an ethic minority, 2) the percentage of the
practice population aged >65 years, and 3) the IMD quintile
attributed to the practice. Other potential explanatory vari-
ables were practice list size, number of patients for each GP
in the practice, whether the practice had postgraduate GP
training status, the rural/ urban mix of the practice popula-
tion, the percentage prevalence of diabetes, and the per-
centage prevalence of hypertension. Prevalence of diabetes
and hypertension were included as treatment with statins is
often indicated in these conditions. We tested for multicol-
linearity by examining the variance inflation factor (VIF)
for each explanatory variable in the model.Sensitivity analyses
We performed five sensitivity analyses to test whether our
model was robust to changes in the four assumptions con-
tained in our model. First we assumed only patients with
heart disease and stroke who had a cholesterol < 5 mmol/l
were taking a statin, as most patients taking a statin will
have a cholesterol lower than 5 mmol/l [32]; second we
assumed the average dose of statin prescribed was the
‘average daily quantity’; third we assumed that only 70% of
prescriptions were dispensed; fourth we assumed that only
60% of prescriptions were dispensed; fifth we assumed that
no patients had a comorbidity of CHD and stroke. These
results are displayed in Additional file 2.Results
Full data were available for 6155 of the 8192 (75.3%)
English general practices, with 40,017,963 patients.
Values for the estimates of prescribing of statins for pri-
mary prevention were normally distributed. Visual inspec-
tion of the scatterplots suggested a linear relationship
between the dependent variable and the percentage of
population from an ethnic minority, quintile of IMD and
the percentage of population over 65 years. There did not
appear to be influential outliers. Table 1 displays the de-
scriptive statistics for the final regression model. An esti-
mated mean of 10.5% (s.d.3.7%) of the practice population
were prescribed a statin for any indication, and 6.3% (s.d.
3.0) were prescribed a statin for primary prevention.
Table 2 displays the final models of the regression
equation. The regression model explained 21.2% of the
variation in estimates of prescribing a statin for primary
prevention. The strongest predictors of prescribing rates
of statins for primary prevention were the prevalence of
diabetes and hypertension. For every 10% increase in the
prevalence of diabetes (e.g. from 3.7% to 4.1%) there was
approximately a 5% increase in the percentage of the
population taking a statin for primary prevention (from
6.3% to 6.6%); and for every 10% increase in the preva-
lence of hypertension (e.g. from 12.5% to 13.7%) there
was approximately a 3% increase in the percentage of
the population taking a statin for primary prevention
(from 6.3% to 6.5%). In a very small number of practices
the rates of estimates of prescribing were so low that in-
sufficient prescriptions were issued to meet the predicted
needs of their secondary care population of patients on
the CHD and Stroke registers (0.5% of practices).
Tests using the variance inflation factor of predictor var-
iables ranged from 1.1 to 2.4, indicating that multicolli-
nearity was not a problem. None of the sensitivity analyses
altered the main findings of the study with one exception.
Reducing the estimate of prescriptions for statins dis-
pensed by the chemist to 70% and to 60% meant that the
predictor variable ‘percentage of population over 65 years’
was no longer statistically significant.
Discussion
Summary
This study derived estimates for rates of prescription of
statins for primary prevention based on data derived from
75% of all general practices in England. We estimated that
10.5% of the registered population were dispensed a statin
and that in 6.3%, primary CVD prevention was the indica-
tion for prescribing. There was evidence for social inequi-
ties with higher ethnicity, older persons and increasing
social deprivation being significant predictors of reduced
prescribing rates of statins for primary prevention. The
prevalence of diabetes and hypertension were strong
predictors of estimates of statin prescribing in primary
Table 1 Descriptive statistics, practice characteristics for practices in England in 2006/2007
n Mean Standard deviation
Prevalence of hypertension 8182 12.53% 3.73%
Prevalence of diabetes 8182 3.73% 1.06%
Percentage from an ethnic minority 8090 10.89% 17.65%
Practice list size, measure in 1000s of patients 8182 6.50 3.96
IMD national quintile. Quintile 5 is most deprived (categorical data) 8182 2.56 n/a
Percentage of population >65 years 8182 15.01% 5.16%
Degree of rurality (Scale 1–8; 1 has highest population density) 8090 5.16 0.65
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An unexpected and important finding was that in a small
minority of practices the estimates of prescribing rates of
statins were so low that there were insufficient doses to
meet the predicted needs of their population of patients
who had already had a stroke or CHD. This study used data
from 2006–7. Since then guidelines have changed which
have increased the indications for prescribing statins for
primary prevention, including lowering the 10 year CVD
risk threshold to 10% and also including patients with
rheumatoid arthritis and chronic kidney disease.
Strengths and limitations
This is the first large scale study estimating the prevalence
of statin prescribing for primary prevention of CVD and
primary prevention in an ethnic minority population. The
entire English population with available data was sampled
which minimised the possibility of selection bias. The prime
limitation is that we did not have access to patient-level
data which meant that we had to estimate the volume of
statins used in primary CVD prevention. We used proxy
measures for the role of social deprivation which may
underestimate social inequalities [28]. There may be inac-
curacies in the data that we have sourced on QOF such as
incorrect Read coding in the medical record, though these
are likely to be small. Prescribing data measures only those
prescriptions that have been both prescribed and dispensed
but we were unable to determine true consumption. SomeTable 2 Regression model showing relation between practice
prevention
R2 = 0.212 n = 6155 Standard
Prevalence of hypertension
Prevalence of diabetes
Percentage from an ethnic minority
Practice list size, measure in 1000s of patients
IMD national quintile (quintile 5 is most deprived)
Percentage of population >65 years
Degree of rurality (Scale 1–8; 1 has highest population density)
Values are percentage difference (adjusted) in statins prescribed for primary prevenpatients may have purchased statins directly from the
pharmacist (over-the-counter use) resulting in a small
underestimate of our total prescribing volumes [30]. The
assumption that all patients with CVD or stroke were tak-
ing a statin unless they had been exception reported by
their practitioner is likely to be an overestimate (thus
underestimating prescribing for primary prevention). This
overestimate is likely to be small, as one English study re-
ported high prescribing rates with 97% of patients with
heart disease were recorded as taking a statin after a heart
attack in 2004/5 [33]. Other authors have reported lower
prescribing rates of statins and we have taken this into ac-
count in the sensitivity analysis [34]. It is possible (although
unlikely) that all eligible patients were prescribed therapy
for primary prevention and none were prescribed therapy
for secondary prevention.
The adjustment for comorbidity is likely to be an over-
estimate as it included other comorbidities (thus over-
estimating prescribing volumes for primary prevention).
We could not determine how many patients were receiv-
ing a statin for peripheral vascular disease. This is an ob-
servational study and as such it does not demonstrate
causation, and because it is an ecological study associa-
tions at the practice level may not apply to individuals.
Comparison with the existing literature
This is the largest study to estimate rates of prescribing of
statins for primary prevention in general practice incharacteristics and the prescribing of statins for primary
ized coefficients Unstandardized
coefficients (β)
95% CI for β P value
0.319 0.299 0.267 to 0.332 <0.001
0.187 0.566 0.477 to 0.655 <0.001
−0.139 −0.026 −0.031 to −0.020 <0.001
−0.114 −0.085 −0.102 to −0.068 <0.001
−0.076 −0.152 −0.203 to −0.102 <0.001
−0.053 −0.032 −0.053 to −0.011 0.002
−0.026 −0.121 −0.228 to −0.014 0.026
tion.
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primary prevention with statins. The estimates for prescrib-
ing rates for primary prevention are similar to another UK
study based in 421 practices in 2008 [22]. An English study
using individual patient data from 2009 reported that 74%
of patients with establish CVD received a prescription for a
statin, which is similar to the sensitivity analysis [34]. Other
studies have reported lower prescribing rates in an elderly
population and that prescribing rates are related to the
prevalence of diabetes and hypertension [19,22].
Conclusions
First there was evidence for inequity with lower estimates
of statin prescribing for primary prevention with respect to
ethnicity, older persons and social deprivation. Second, the
estimated levels of statin prescribing were insufficient to
offer adequate primary CVD prevention in some practices.
The reasons for low prescribing rates for statins are uncer-
tain but may include downward prescribing cost pressures,
the use of lower than recommended doses, patient factors,
and the lack of a financial incentive at the time for primary
prevention of CVD. In light of the findings of our study to-
gether with two smaller studies demonstrating under pre-
scribing of statins in primary prevention of CVD, further
research using individual patient level data targeting socially
deprived groups, ethnic minority groups and elderly groups
is indicated [19,22].
Additional files
Additional file 1: Computations for numbers of patients receiving a
statin for primary prevention.
Additional file 2: Sensitivity Analyses.
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